Eli Lilly signed a research and licensing agreement worth up to $2.75 billion with Insilico Medicine.
The Story
The deal aims to advance AI-driven drug discovery and development.
Why It Matters
A pharma giant is betting billions on AI for drug discovery, not just experimentation. For European CROs and biotechs, this signals the shift from "if" to "how" AI integrates into R&D, especially with EU AI Act enforcement looming. It's about governed execution, not just hype.
What To Do About It
Don't chase shiny new tools. Start by leveraging your existing Microsoft 365 Copilot capabilities for initial R&D process analysis. I can help map your current workflows and identify secure, EU-compliant AI integration points in 2-3 weeks.
Sources
Related Signals
Flagright, a new AI operating system for compliance, just secured $12.5M in funding.
17 Jun 2026
Pharma compliance is actively adapting to new AI tools and emerging regulation.
6 Jun 2026
Weverse Brain was selected for South Korea's Ministry of Science and ICT's "Advanced GPU Utilization Support Project".
2 Jun 2026